Shares of BioCryst Pharmaceuticals (BCRX +3.4%) get a lift after the company reveals its BCX4208...

|About: BioCryst Pharmaceuticals,... (BCRX)|By:, SA News Editor

Shares of BioCryst Pharmaceuticals (BCRX +3.4%) get a lift after the company reveals its BCX4208 gout drug met its primary endpoint in a Phase 2b randomized, double-blind, dose-response study. CEO Jon Stonehouse says the next big step is to find a partner for lead development for the drug that he says has a market potential of $500M.